AU2016309948B2 - Connexin 45 inhibition for therapy - Google Patents

Connexin 45 inhibition for therapy Download PDF

Info

Publication number
AU2016309948B2
AU2016309948B2 AU2016309948A AU2016309948A AU2016309948B2 AU 2016309948 B2 AU2016309948 B2 AU 2016309948B2 AU 2016309948 A AU2016309948 A AU 2016309948A AU 2016309948 A AU2016309948 A AU 2016309948A AU 2016309948 B2 AU2016309948 B2 AU 2016309948B2
Authority
AU
Australia
Prior art keywords
sequence
inhibitor
vector
ventricular
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016309948A
Other languages
English (en)
Other versions
AU2016309948A1 (en
Inventor
Peter FAHMY
Eddy KIZANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Western Sydney Local Health District
Original Assignee
University of Sydney
Western Sydney Local Health District
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903282A external-priority patent/AU2015903282A0/en
Application filed by University of Sydney, Western Sydney Local Health District filed Critical University of Sydney
Publication of AU2016309948A1 publication Critical patent/AU2016309948A1/en
Application granted granted Critical
Publication of AU2016309948B2 publication Critical patent/AU2016309948B2/en
Priority to AU2021215254A priority Critical patent/AU2021215254A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016309948A 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy Active AU2016309948B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021215254A AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903282A AU2015903282A0 (en) 2015-08-14 Connexin 45 Inhibition for Therapy
AU2015903282 2015-08-14
PCT/AU2016/050740 WO2017027910A1 (en) 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021215254A Division AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Publications (2)

Publication Number Publication Date
AU2016309948A1 AU2016309948A1 (en) 2018-03-08
AU2016309948B2 true AU2016309948B2 (en) 2021-05-20

Family

ID=58050389

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016309948A Active AU2016309948B2 (en) 2015-08-14 2016-08-12 Connexin 45 inhibition for therapy
AU2021215254A Abandoned AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021215254A Abandoned AU2021215254A1 (en) 2015-08-14 2021-08-13 Connexin 45 Inhibition for Therapy

Country Status (6)

Country Link
US (1) US10709726B2 (enExample)
EP (2) EP3334746B1 (enExample)
JP (2) JP2018529759A (enExample)
AU (2) AU2016309948B2 (enExample)
CA (1) CA3033909A1 (enExample)
WO (1) WO2017027910A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200061210A1 (en) * 2018-08-27 2020-02-27 BioViva USA, Inc. Novel method for gene therapy using intranasal administration of genetically modified viral vectors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053600A2 (en) * 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2012065143A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA962806A (en) 1970-06-04 1975-02-18 Ontario Research Foundation Surgical prosthetic device
US4281669A (en) 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
US4101984A (en) 1975-05-09 1978-07-25 Macgregor David C Cardiovascular prosthetic devices and implants with porous systems
IT1196836B (it) 1986-12-12 1988-11-25 Sorin Biomedica Spa Protesi in materiale polimerico con rivestimento di carbonio biocompatibile
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5163958A (en) 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5236457A (en) 1992-02-27 1993-08-17 Zimmer, Inc. Method of making an implant having a metallic porous surface
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE19855421C2 (de) 1998-11-02 2001-09-20 Alcove Surfaces Gmbh Implantat
CA2425665C (en) 2000-10-31 2013-07-16 Cook Incorporated Coated implantable medical device
US7803149B2 (en) 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
CN1725988A (zh) 2002-11-13 2006-01-25 斯特根有限公司 具有多孔层的医用装置及其制造方法
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US20180099029A9 (en) 2010-04-15 2018-04-12 Mount Sinai School Of Medicine Serca2 therapeutic compositions and methods of use
EP2655621B1 (en) * 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
FI3597749T3 (fi) 2012-05-25 2023-10-09 Univ California Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
EP2877213B1 (en) 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP2880171B1 (en) 2012-08-03 2018-10-03 The Regents of The University of California Methods and compositions for controlling gene expression by rna processing
KR101656236B1 (ko) 2012-10-23 2016-09-12 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
PT3363902T (pt) 2012-12-06 2019-12-19 Sigma Aldrich Co Llc Modificação e regulação de genoma baseadas em crispr
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP4234696A3 (en) 2012-12-12 2023-09-06 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
KR20150105956A (ko) 2012-12-12 2015-09-18 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
CA2951721C (en) * 2014-06-12 2023-09-26 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053600A2 (en) * 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2012065143A1 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas

Also Published As

Publication number Publication date
EP4043074A1 (en) 2022-08-17
JP2018529759A (ja) 2018-10-11
WO2017027910A1 (en) 2017-02-23
AU2016309948A1 (en) 2018-03-08
CA3033909A1 (en) 2017-02-23
EP3334746A1 (en) 2018-06-20
AU2021215254A1 (en) 2021-09-02
EP3334746B1 (en) 2021-11-24
US20190030063A1 (en) 2019-01-31
EP3334746A4 (en) 2019-04-24
JP2021176848A (ja) 2021-11-11
JP7668686B2 (ja) 2025-04-25
US10709726B2 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
AU2018311504B2 (en) Cellular models of and therapies for ocular diseases
Galbiati et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism
Mearini et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
KR20200057766A (ko) 페닐케톤뇨증을 치료하기 위한 프로모터 및 인핸서 조합을 포함하는 벡터
US20230192784A1 (en) KLF Induced Cardiomyogenesis
US20200308582A1 (en) Kcnk3-based gene therapy of cardiac arrhythmia
US20220023384A1 (en) Mybpc3 polypeptides and uses thereof
Sultan et al. Exploring small nucleolar RNA host gene 3 as a therapeutic target in breast cancer through metabolic reprogramming
CN116887868A (zh) 达农病的治疗
CN116171325A (zh) 用于eEF1A2的基因疗法载体及其用途
EP3285813B1 (en) Smad7 gene delivery as a therapeutic
JP7668686B2 (ja) 治療用コネキシン４５阻害剤
US20240408239A1 (en) Compositions and methods to prevent, inhibit or treat neurodegenerative diseases
Pratt et al. Evaluating the feasibility of gene replacement strategies to treat MTRFR deficiency
Li et al. Cellular-level analyses of SCN5A mutations in left ventricular noncompaction cardiomyopathy suggest electrophysiological mechanisms for ventricular tachycardia
US20230313182A1 (en) Preparation method for diabetes early warning and/or diagnostic reagent kit based on hsa-mir-320a, medicament for preventing diabetes, screening method for medicament, and preparation method therefor
CN118697878B (zh) Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
US20220349876A1 (en) Use of dkk1 inhibitor in prevention and/or treatment of tumor cachexia and diseases associated with diabetes
WO2025030125A1 (en) Applications of cmya5 minigenes
CN120860261A (zh) Angulin-1基因和/或Angulin-1蛋白在制备抗衰老及治疗衰老相关疾病的产品中的应用
Sacal Inherited Arrhythmogenic Cardiac Diseases and the Kir2. 1-NaV1. 5 Channelosome
WO2025060840A1 (zh) Bcor和Zc3h12a在预防和治疗慢性感染中的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)